GLP-1 drugs and eating disorders: what TikTok gets wrong

What did @imaginary.magdeline actually say?

The claim here is thin, literally. The creator says they believe they are "getting kinda chubby" and frames this as something a mother figure would want people to understand, offering it as a form of help. That is essentially the full substance of the health-relevant content. This video is tagged under GLP-1 content, which means the implication, whether intended or not, is that GLP-1 medication use is connected to the weight observation.

The hashtags tell a more complicated story. Tags like #ana and #bed alongside #copingwithhumor suggest this video may be embedded in eating disorder community spaces, where weight gain commentary carries very different weight, no pun intended. The "ED Sheeran" hashtag appears to be a common workaround to avoid content moderation on eating disorder topics. That context matters enormously when evaluating what this video is actually communicating and to whom.

Does the science back this up?

There is no coherent scientific claim to evaluate here, because the transcript does not make one. What we can do is address the implied territory: GLP-1 receptor agonists and weight change. On that front, the science is actually pretty clear, and it goes in the opposite direction of "getting chubby."

Semaglutide, the active ingredient in Ozempic and Wegovy, produced an average body weight reduction of 14.9% over 68 weeks in the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine). Tirzepatide, studied in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), showed reductions up to 22.5% in the highest dose group. These are not subtle effects. GLP-1 medications are among the most effective pharmacological tools for weight reduction ever studied in large randomized controlled trials.

Weight gain on GLP-1 medications does happen, but almost exclusively after stopping them. Davies et al. (2023, Diabetes, Obesity and Metabolism) found significant weight regain within one year of discontinuation. So if someone is "getting kinda chubby" while on a GLP-1, that warrants a clinical conversation, not a TikTok caption.

What did they get wrong (or right)?

Wrong: If the implication is that GLP-1 use causes weight gain during active treatment, that is not supported by the evidence. The major clinical trials show consistent, significant weight loss as the primary outcome. Framing GLP-1 use and weight gain as connected, even obliquely, spreads confusion in a space that is already crowded with misinformation.

Right: The creator does not make any specific dosing claims, does not name a medication, and does not tell anyone what to take. That keeps the video from crossing into the more dangerous territory of unqualified medical advice. Credit where it is due.

The bigger concern is contextual. Posting weight-related content with eating disorder-coded hashtags, even under the banner of humor, can reinforce harmful body image narratives for a vulnerable audience. A 62,800-view video is not a private conversation. The #copingwithhumor framing does not neutralize the potential impact on someone already struggling with disordered eating.

What should you actually know?

If you are on a GLP-1 medication and experiencing unexpected weight gain, there are legitimate clinical explanations worth discussing with your prescriber. These include inadequate dosing for your individual metabolism, medication non-adherence, hormonal factors, or changes in appetite signaling that vary person to person. It does not mean the drug is not working for everyone, and it does not mean you should self-adjust your dose.

If you are in an eating disorder recovery space and encountering GLP-1 content, that intersection is genuinely complicated. Research is actively examining whether GLP-1 agonists are appropriate for people with restrictive eating disorder histories. Giel et al. (2023, European Eating Disorders Review) raised caution about using appetite-suppressing medications in populations where reduced appetite is already a pathological feature. This is not settled science, and your care team needs to be part of that conversation.

FormBlends is a regulated telehealth platform. We do not recommend specific doses, and we do not claim compounded GLP-1 products are equivalent to FDA-approved brand-name drugs. If you have questions about GLP-1 therapy, that conversation belongs with a licensed clinician who knows your full medical history.